Get the Stockscreener App
0.2852
17.62%
-0.061
Clearmind Medicine Inc stock is traded at $0.2852, with a volume of 8.85M.
It is down -17.62% in the last 24 hours and down -70.00% over the past month.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
See More
Previous Close:
$0.3462
Open:
$0.2967
24h Volume:
8.85M
Relative Volume:
1.40
Market Cap:
$1.56M
Revenue:
-
Net Income/Loss:
$-6.78M
P/E Ratio:
-0.00668
EPS:
-42.6996
Net Cash Flow:
$-4.67M
1W Performance:
-58.32%
1M Performance:
-70.00%
6M Performance:
-70.60%
1Y Performance:
-80.60%
1-Day Range:
$0.28
$0.324
1-Week Range:
$0.24
$0.71
52-Week Range:
$0.24
$2.18
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.2852 | 2.20M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Clearmind Medicine Inc Stock (CMND) Latest News
Is Clearmind Medicine Inc. stock supported by strong fundamentals2025 Key Lessons & Capital Efficiency Focused Strategies - newser.com
How sentiment analysis helps forecast Clearmind Medicine Inc.July 2025 WrapUp & Daily Volume Surge Signals - newser.com
Clearmind Medicine Inc Stock Analysis and ForecastDividend Reinvestment Plans & Invest Now – Opportunity Window Closing - earlytimes.in
Intraday pattern recognizer results for Clearmind Medicine Inc.Weekly Stock Report & High Accuracy Trade Alerts - newser.com
Can Clearmind Medicine Inc. (CWY0) stock double in coming yearsTrade Analysis Report & Risk Controlled Daily Trade Plans - newser.com
Clearmind Medicine receives approval for AUD clinical trial site By Investing.com - Investing.com Nigeria
Clearmind Medicine (CMND) Stock Soars Thursday: What's Going On? - Benzinga
Nasdaq Down Over 150 Points; Disney Shares Fall After Q4 Results - Benzinga
Clearmind Medicine stock soars after receiving final approval for AUD trial By Investing.com - Investing.com Nigeria
Clearmind Medicine stock soars after receiving final approval for AUD trial - Investing.com India
Clearmind Medicine receives approval for AUD clinical trial site - Investing.com
Clearmind (NASDAQ: CMND) adds Hadassah to FDA-regulated Phase 1/2a AUD trial - Stock Titan
Why Clearmind Medicine Inc. stock could benefit from AI revolutionQuarterly Profit Report & Technical Entry and Exit Tips - newser.com
Price momentum metrics for Clearmind Medicine Inc. explainedM&A Rumor & Safe Entry Point Identification - newser.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Volatility clustering patterns for Clearmind Medicine Inc.July 2025 Weekly Recap & Technical Analysis for Trade Confirmation - newser.com
Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment - The Manila Times
Clearmind Medicine Inc. Announces Patent Publication for Non-Hallucinogenic Depression Treatment in China - Quiver Quantitative
Clearmind (NASDAQ: CMND) receives CNIPA notice of MEAI depression patent publication - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Clearmind completes first patient cohort in AUD treatment trial By Investing.com - Investing.com Canada
Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder - The Manila Times
Clearmind completes first patient cohort in AUD treatment trial - Investing.com
Clearmind Medicine Inc. Advances CMND-100 Clinical Trial for Alcohol Use Disorder Treatment Targeting $20 Billion Market - Quiver Quantitative
Is Clearmind Medicine Inc. stock positioned for long term growth2025 Volume Leaders & Community Consensus Trade Signals - newser.com
Clearmind Medicine (NASDAQ: CMND) completes first AUD cohort; 6 patients treated - Stock Titan
What earnings margins imply for Clearmind Medicine Inc. (CWY0) stockMarket Volume Report & High Win Rate Trade Tips - newser.com
What momentum shifts mean for Clearmind Medicine Inc.Portfolio Update Summary & AI Powered Trade Plan Recommendations - newser.com
Will Clearmind Medicine Inc. (CWY0) stock outperform Dow Jones2025 Investor Takeaways & Weekly Top Gainers Alerts - newser.com
Why Clearmind Medicine Inc. stock is trending among retail tradersSwing Trade & Advanced Technical Analysis Signals - newser.com
Working capital per share of Clearmind Medicine Inc. – BER:CWY0 - TradingView
Why Is Clearmind Stock Down Today? - inkl
Clearmind Medicine receives Nasdaq non-compliance notice over equity rule By Investing.com - Investing.com South Africa
Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - The Manila Times
Clearmind Medicine receives Nasdaq non-compliance notice over equity rule - Investing.com
Will Clearmind Medicine Inc. (CWY0) stock hit analyst forecastsAnalyst Upgrade & Scalable Portfolio Growth Methods - newser.com
Is Clearmind Medicine Inc. (CWY0) stock a buy for dividend portfolios2025 Price Momentum & Free Expert Approved Momentum Trade Ideas - newser.com
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):